Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating hypercholesterolemia: looking forward.

Antonio M Gotto1

  • 1The Joan and Sanford I. Weill Medical College of Cornell University, New York, New York 10021, USA. pat2004@med.cornell.edu

Clinical Cardiology
|January 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LDL atherogenicity determined by size, density, oxidation, apolipoprotein(a), and electronegativity: an updated review.

Frontiers in cardiovascular medicine·2025
Same author

Atherosclerotic features in patients with heart failure.

Archives of medical science : AMS·2025
Same author

HDL-free cholesterol influx into macrophages and transfer to LDL correlate with HDL-free cholesterol content.

Journal of lipid research·2024
Same author

Comparative Analysis of Atherogenic Lipoproteins L5 and Lp(a) in Atherosclerotic Cardiovascular Disease.

Current atherosclerosis reports·2024
Same author

Serum opacity factor normalizes erythrocyte morphology in Scarb1<sup>-/-</sup> mice in an HDL-free cholesterol-dependent way.

Journal of lipid research·2023
Same author

The pathophysiology of excess plasma-free cholesterol.

Current opinion in lipidology·2023
Same journal

In-Hospital Cardiac Arrest Detection Performance Analysis and Comparison on Effective Feature Selection.

Clinical cardiology·2026
Same journal

Interpreting the Association Between Diuretic Intensity Score and Mortality: The Potential Roles of Diuretic Responsiveness and Mineralocorticoid Receptor Antagonist Therapy.

Clinical cardiology·2026
Same journal

Heart Failure With Preserved Ejection Fraction-Like Phenotype in Coronary Artery Disease and Obstructive Sleep Apnea: Insights From the RICCADSA Cohort.

Clinical cardiology·2026
Same journal

Ethanol Infusion Into the Vein of Marshall for Atrial Fibrillation: Clinical Efficacy and Technical Limitations.

Clinical cardiology·2026
Same journal

Methodological Considerations Regarding Diuretic Intensity Score and Mortality in Hospitalized Heart Failure Patients.

Clinical cardiology·2026
Same journal

Inpatient Outcomes and Complications After Left Atrial Appendage Occlusion in Rural Versus Urban Hospitals in the United States.

Clinical cardiology·2026
See all related articles

Newer statins like rosuvastatin and pitavastatin show promise for lowering low-density lipoprotein (LDL) cholesterol more effectively. Future treatments may combine therapies for greater lipid reduction.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Hypercholesterolemia management has advanced, yet many patients remain undertreated, facing elevated LDL cholesterol and coronary event risks.
  • Statins, inhibiting HMG-CoA reductase, are potent lipid-lowering agents, with newer formulations offering enhanced efficacy.

Purpose of the Study:

  • To review the efficacy of emerging statins and other lipid-lowering agents in managing hypercholesterolemia.
  • To discuss the potential of novel therapeutic approaches beyond HMG-CoA reductase inhibition.

Main Methods:

  • Review of clinical trial data for rosuvastatin and pitavastatin.
  • Discussion of ezetimibe and other investigational lipid-lowering drugs.

Main Results:

Related Experiment Videos

  • Rosuvastatin demonstrated superior LDL cholesterol reduction compared to other statins in preliminary studies.
  • Pitavastatin also shows potential for greater potency than current statins.

Conclusions:

  • Emerging statins and novel agents like ezetimibe offer improved hypercholesterolemia management options.
  • Further research is needed to fully establish the clinical utility of these new therapies.